Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis.
The tumor microenvironment (TME) is a key determinant of metastatic efficiency. We performed a quantitative high throughput screen (qHTS) of diverse medicinal-chemistry tractable scaffolds (44,420 compounds) and pharmacologically active small molecules (386 compounds) using a layered organotypic, robust assay representing the ovarian cancer (OvCa) metastatic TME. This 3D model contains primary human mesothelial cells, fibroblasts and extracellular matrix, to which fluorescently-labeled OvCa cells are added. Initially, 100 compounds inhibiting OvCa adhesion/invasion to the 3D model in a dose-dependent manner were identified. Of those, eight compounds were confirmed active in five high-grade serous OvCa cell lines, and were further validated in secondary in vitro and in vivo biological assays. Two tyrosine kinase inhibitors, PP-121 and Milciclib, and a previously unreported compound, NCGC00117362, were selected because they had potency at 1μΜ in vitro. Specifically, Milciclib and NCGC00117362 inhibited OvCa adhesion, invasion and proliferation, while PP-121 inhibited OvCa invasion and proliferation. Using in situ kinase profiling and cellular thermal shift assays, we found that Milciclib targeted Cdk2 and Cdk6, and PP-121 targeted mTOR. In vivo, all three compounds prevented OvCa adhesion/invasion and metastasis, prolonged survival and reduced omental tumor growth in an intervention study. To evaluate the clinical potential of NCGC00117362, structure-activity-relationship studies were performed. Four close analogs of NCGC00117362 efficiently inhibited cancer aggressiveness in vitro and metastasis in vivo. Collectively, these data show that a complex 3D culture of the TME is effective in qHTS. The three compounds identified have promise as therapeutics for prevention and treatment of OvCa metastasis.